Table 2.
Hazard ratio for relapse-free and overall survival according to multivariable Cox regression models
| Relapse-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p | Hazard ratio | 95% CI | p | |
| Cytarabine dose | ||||||
| HiDAC | Reference | Reference | ||||
| IDAC | 0.900 | 0.650–1.246 | 0.530 | 1.094 | 0.721–1.660 | 0.670 |
| ELN risk group | ||||||
| Intermediate | Reference | Reference | ||||
| Favorable | 0.704 | 0.514–0.965 | 0.029 | 0.435 | 0.273–0.694 | < 0.001 |
| Adverse | 1.147 | 0.745–1.767 | 0.540 | 1.771 | 0.988–3.174 | 0.055 |
| Number of 7 + 3 induction cycles | ||||||
| 1 cycle | 1.603 | 1.195–2.151 | 0.002 | 1.758 | 1.221–2.532 | 0.002 |
| 2 cycles | Reference | Reference | ||||
| Age (per 10 years) | 1.012 | 0.999–1.025 | 0.120 | 1.021 | 1.001—1.041 | 0.036 |
| Sex, Male | 1.151 | 0.860–1.539 | 0.350 | 1.163 | 0.788–1.718 | 0.450 |
| ECOG, > 1 | 1.071 | 0.704–1.629 | 0.750 | 1.653 | 1.001–2.728 | 0.050 |
| HCT-CI, > 1 | 1.220 | 0.887–1.677 | 0.220 | 1.425 | 0.968–2.099 | 0.072 |
| AML type | ||||||
| de novo | Reference | Reference | ||||
| sAML | 0.807 | 0.462–1.410 | 0.450 | 1.033 | 0.548–1.947 | 0.920 |
| tAML | 1.266 | 0.795–2.015 | 0.320 | 1.215 | 0.657–2.246 | 0.540 |
HiDAC/IDAC high-dose/intermediate-dose cytarabine; sAML secondary AML; tAML treatment-related AML; ECOG clinical performance status according to ECOG criteria; HCT-CI hematopoietic cell transplantation-comorbidity index; 7 + 3 induction treatment with standard-dose cytarabine for 7 d and daunorubicin for 3 d; CR1 first complete remission